Signaling pathways involved in DNA synthesis and migration in response to lysophosphatidic acid and low-density lipoprotein in coronary artery smooth muscle cells

Vascular Pharmacology

Volumn 50, Issue 5-6, 2009, Pages 178-184

  Komachi, Mayumi ^a   Damirin, Alatangaole ^b   Malchinkhuu, Enkhzol ^a   Mogi, Chihiro ^a   Tobo, Masayuki ^a   Ohta, Hideo ^c   Sato, Koichi ^a   Tomura, Hideaki ^a   Okajima, Fumikazu ^a  

^a GUNMA UNIVERSITY   (Japan)

^b INNER MONGOLIA UNIVERSITY   (China)

^c KIRIN BREWERY CO LTD   (Japan)

Author keywords

Ki16425; Low density lipoprotein; Lysophosphatidic acid; Vascular smooth muscle cell

Indexed keywords

3 [4 [4 [[1 (2 CHLOROPHENYL)ETHOXY]CARBONYLAMINO] 3 METHYL 5 ISOXAZOLYL]BENZYLSULFANYL]PROPANOIC ACID; CALCINEURIN; CALCIUM; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; HIGH DENSITY LIPOPROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; PERTUSSIS TOXIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE;

CALCINEURIN; CELL MOVEMENT; CELLS, CULTURED; CORONARY VESSELS; DNA; HUMANS; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MYOCYTES, SMOOTH MUSCLE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 61349091650     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.01.004     Document Type: Article

References (48)

1. Assmann G., and Gotto Jr. A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 109 23 Suppl 1 (2004) III8-III14
2. Auge N., Andrieu N., Negre-Salvayre A., Thiers J.C., Levade T., and Salvayre R. The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J. Biol. Chem. 271 (1996) 19251-19255
3. Auge N., Nikolova-Karakashian M., Carpentier S., Parthasarathy S., Negre-Salvayre A., Salvayre R., Merrill Jr. A.H., and Levade T. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J. Biol. Chem. 274 (1999) 21533-21538
4. Auge N., Garcia V., Maupas-Schwalm F., Levade T., Salvayre R., and Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1990-1995
5. Autio I., Jaakkola O., Solakivi T., and Nikkari T. Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture. FEBS Lett. 277 (1990) 247-249
6. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ. Res. 95 (2004) 764-772
7. Crabtree G.R., and Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 109 (2002) S67-79 Suppl
8. Damirin A., Tomura H., Komachi M., Liu J.P., Mogi C., Tobo M., Wang J.Q., Kimura T., Kuwabara A., Yamazaki Y., Ohta H., Im D.S., Sato K., and Okajima F. Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H2513-2522
9. Eguchi S., Frank G.D., Mifune M., and Inagami T. Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem. Soc. Trans. 31 Pt 6 (2003) 1198-1202
10. Ishii I., Fukushima N., Ye X., and Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73 (2004) 321-354
11. Kalmes A., Vesti B.R., Daum G., Abraham J.A., and Clowes A.W. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ. Res. 87 (2000) 92-98
12. Kawakami A., Tanaka A., Chiba T., Nakajima K., Shimokado K., and Yoshida M. Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation 108 (2003) 2679-2688
13. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., Ui M., and Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276 (2001) 31780-31785
14. Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., Murakami M., and Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1283-1288
15. Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., Sekiguchi A., Ishiwara M., Im D.S., Sato K., Murakami M., and Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281 (2006) 37457-37467
16. Kohno M., Yokokawa K., Yasunari K., Kano H., Minami M., Ueda M., and Yoshikawa J. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ. Res. 81 (1997) 585-590
17. Kon J., Sato K., Watanabe T., Tomura H., Kuwabara A., Kimura T., Tamama K., Ishizuka T., Murata N., Kanda T., Kobayashi I., Ohta H., Ui M., and Okajima F. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells. J. Biol. Chem. 274 (1999) 23940-23947
18. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr. Opin. Lipidol. 14 (2003) 421-430
19. Lipskaia L., Pourci M.L., Delomenie C., Combettes L., Goudouneche D., Paul J.L., Capiod T., and Lompre A.M. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ. Res. 92 (2003) 1115-1122
20. McMurray H.F., Parthasarathy S., and Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. 92 (1993) 1004-1008
21. Meyer zu Heringdorf D., and Jakobs K.H. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta 1768 (2007) 923-940
22. Murata N., Sato K., Kon J., Tomura H., Yanagita M., Kuwabara A., Ui M., and Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352 (2000) 809-815
23. Nakajima K., Nakano T., and Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin. Chim. Acta 367 (2006) 36-47
24. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., Vahabzadeh K., Hama S., Hough G., Kamranpour N., Berliner J.A., Lusis A.J., and Fogelman A.M. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45 (2004) 993-1007
25. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Godecke A., Ishii I., Kleuser B., Schafers M., Fobker M., Zidek W., Assmann G., Chun J., and Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113 (2004) 569-581
26. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., Kimura T., Tobo M., Yamazaki Y., Watanabe T., Yagi M., Sato M., Suzuki R., Murooka H., Sakai T., Nishitoba T., Im D.S., Nochi H., Tamoto K., Tomura H., and Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64 (2003) 994-1005
27. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?. Biochim. Biophys. Acta 1582 (2002) 132-137
28. Okajima, F., Sato, K., Kimura, T., in press. Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr. J. doi:10.1507/endocrj.K08E-228.
29. Panchatcharam M., Miriyala S., Yang F., Rojas M., End C., Vallant C., Dong A., Lynch K., Chun J., Morris A.J., and Smyth S.S. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 103 (2008) 662-670
30. Pidkovka N.A., Cherepanova O.A., Yoshida T., Alexander M.R., Deaton R.A., Thomas J.A., Leitinger N., and Owens G.K. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ. Res. 101 (2007) 792-801
31. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116 (2006) 3090-3100
32. Rother E., Brandl R., Baker D.L., Goyal P., Gebhard H., Tigyi G., and Siess W. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108 (2003) 741-747
33. Sachinidis A., Kettenhofen R., Seewald S., Gouni-Berthold I., Schmitz U., Seul C., Ko Y., and Vetter H. Evidence that lipoproteins are carriers of bioactive factors. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2412-2421
34. Scott-Burden T., Resink T.J., Hahn A.W., Baur U., Box R.J., and Buhler F.R. Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J. Biol. Chem. 264 (1989) 12582-12589
35. Shimizu T., Nakazawa T., Cho A., Dastvan F., Shilling D., Daum G., and Reidy M.A. Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteries. Circ. Res. 101 (2007) 995-1000
36. Siess W., Zangl K.J., Essler M., Bauer M., Brandl R., Corrinth C., Bittman R., Tigyi G., and Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 96 (1999) 6931-6936
37. Tamama K., Kon J., Sato K., Tomura H., Kuwabara A., Kimura T., Kanda T., Ohta H., Ui M., Kobayashi I., and Okajima F. Extracellular mechanism through the EDG family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem. J. 353 (2001) 139-146
38. Tamama K., Tomura H., Sato K., Malchinkhuu E., Damirin A., Kimura T., Kuwabara A., Murakami M., and Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 178 (2005) 19-23
39. Tomono M., Toyoshima K., Ito M., Amano H., and Kiss Z. Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. Arch. Biochem. Biophys. 353 (1998) 374-378
40. van Meeteren L.A., and Moolenaar W.H. Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46 (2007) 145-160
41. Wamhoff B.R., Lynch K.R., Macdonald T.L., and Owens G.K. Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1454-1461
42. Wu J., and Cunnick J.M. Trans-regulation of epidermal growth factor receptor by lysophosphatidic acid and G protein-coupled receptors. Biochim. Biophys. Acta 1582 (2002) 100-106
43. Xu Y.J., Rathi S.S., Chapman D.C., Arneja A.S., and Dhalla N.S. Mechanisms of lysophosphatidic acid-induced DNA synthesis in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 41 (2003) 381-387
44. Yamada T., Sato K., Komachi M., Malchinkhuu E., Tobo M., Kimura T., Kuwabara A., Yanagita Y., Ikeya T., Tanahashi Y., Ogawa T., Ohwada S., Morishita Y., Ohta H., Im D.S., Tamoto K., Tomura H., and Okajima F. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J. Biol. Chem. 279 (2004) 6595-6605
45. Yart A., Chap H., and Raynal P. Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway. Biochim. Biophys. Acta 1582 (2002) 107-111
46. Yellaturu C.R., Ghosh S.K., Rao R.K., Jennings L.K., Hassid A., and Rao G.N. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem. J. 368 (2002) 183-190
47. Yoshida K., Nishida W., Hayashi K., Ohkawa Y., Ogawa A., Aoki J., Arai H., and Sobue K. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 108 (2003) 1746-1752
48. Zhang C., Baker D.L., Yasuda S., Makarova N., Balazs L., Johnson L.R., Marathe G.K., McIntyre T.M., Xu Y., Prestwich G.D., Byun H.S., Bittman R., and Tigyi G. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J. Exp. Med. 199 (2004) 763-774